Program Director:       
    Celestia S. Higano, MD, FACP
    University of Washington
    Seattle, Washington

Faculty:       
    Andrew Armstrong, MD, ScM, FACP
    Duke University Medical Center
    Durham, North Carolina

    Alan H. Bryce, MD
    Mayo Clinic Arizona
    Scottsdale, Arizona

    Tanya B. Dorff, MD
    USC Keck School of Medicine/Norris Comprehensive Cancer Center
    Los Angeles, California
        
 

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty, CCO staff, and NCCN staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty:
Andrew Armstrong, MD, ScM, FACP, has disclosed that he has received consulting fees from Astellas/Medivation, Bayer, Dendreon, Eisai, and Janssen and funds for research support from Active Biotech/Ipsen, Astellas/Medivation, Bayer, Dendreon, Gilead, Janssen, Novartis, Pfizer, and sanofi-aventis.

Alan H. Bryce, MD, has no real or apparent conflicts of interest to report.

Tanya B. Dorff, MD, has disclosed that she has received consulting fees from Astellas, Bayer, Dendreon, Genentech, and Pfizer.

Celestia S. Higano, MD, FACP, has disclosed that she has received consulting fees from AbbVie, Astellas/Medivation, Bayer, BHR Pharma, Blue Earth, Cato Research, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Emergent BioSolutions, Ferring, Medivation, MorphoSys, Orion Corporation, PAREXEL International, Pfizer, and Valeant/Dendreon and funds for research support from Algeta/Bayer, Aragon Pharmaceuticals, AstraZeneca, Dendreon, Emergent BioSolutions, Exelixis, Genentech, Medivation, Millennium, sanofi-aventis, and Teva.

Maha Hussain, MD, has disclosed that she has received consulting fees from AbbVie and Bayer and funds for research support from Bayer, Genentech/Roche, Medivation, and Pfizer.

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Roche, sanofi-aventis, and Tyme; has received funds for research support from Agensys, Celgene, Dendreon, Eli Lilly, Johnson & Johnson, Millennium, OncoGeneX, Progenics, Roche, sanofi-aventis; and has ownership interest in Bellicum and Tyme.

Staff:
The activity planning staff listed below has no relevant financial relationships to disclose:
CCO: Timothy A. Quill, PhD; Rachael M. Andrie, PhD; Kevin Obholz, PhD.
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rashmi Kumar, PhD; Joan S. McClure, MS; Deborah Moonan, RN, BSN; Lisa Perfidio; Kathy Smith.

The NCCN activity planning staff listed below has disclosed the following relevant financial relationships:

Mercedes De La Hoz
Pfizer Inc.: Other financial benefit

The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose:
Deborah Freedman-Cass, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this CE activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Nurse Planner: Kristina M. Gregory, RN, MSN, OCN, is the nurse planner for all NCCN educational activities.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.